ANIP:NSD-ANI Pharmaceuticals, Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 28.31

Change

+0.11 (+0.39)%

Market Cap

USD 0.35B

Volume

0.11M

Average Target Price

USD 40.00 (+41.29%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company offers pharmaceuticals for the treatment of breast cancer, hypertension, ventricular arrhythmias, stage D2 metastatic carcinoma of the prostate, depression, diarrhea, infections, vasomotor symptoms of menopause, pain caused by osteoarthritis and rheumatoid arthritis, epilepsy, arrhythmia, obsessive-compulsive disorder and social anxiety disorder, ulcerative colitis, salt and fluid retention, manic episodes of bipolar disorder, ulcerative colitis, proctosigmoiditis, ocular conditions, metastatic prostate cancer, arrhythmia, migraine headache, and enterocolitis caused by staphylococcus aureus. It also provides aspirin and extended-release dipyridamole; Cholestyramine, an adjunctive therapy to diet for the reduction of elevated serum cholesterol; Ezetimibe-Simvastatin to lower high cholesterol and triglyceride levels; Fenofibrate, a peroxisome proliferator receptor alpha activator; Hydrocortisone rectal cream for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Morphine Sulfate, an oral solution for acute and chronic pain management; Nimodipine to enhance neurological outcomes; and Terbutaline Sulfate for the prevention and reversal of bronchospasm. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-02 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

+1.53 (+5.74%)

USD9.90B N/A N/A
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
CRON Cronos Group Inc

+0.23 (+2.76%)

USD3.02B 28.99 N/A
PCRX Pacira BioSciences, Inc

+0.81 (+1.34%)

USD2.63B 20.62 59.76
APHA Aphria Inc

+0.65 (+8.50%)

USD2.23B 25.59 454.68
IRWD Ironwood Pharmaceuticals, Inc

-0.25 (-2.06%)

USD1.90B 16.98 14.02
ATNX Athenex, Inc

+0.24 (+1.80%)

USD1.24B N/A N/A
ENDP Endo International plc

+0.45 (+8.79%)

USD1.18B N/A 9.49
TLRY Tilray, Inc

+0.57 (+7.06%)

USD1.17B N/A N/A

ETFs Containing ANIP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -54.09% 19% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.09% 19% F 5% F
Trailing 12 Months  
Capital Gain -52.88% 18% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.88% 18% F 5% F
Trailing 5 Years  
Capital Gain -35.76% 59% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.76% 59% F 20% F
Average Annual (5 Year Horizon)  
Capital Gain 6.37% N/A N/A 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.37% N/A N/A 52% F
Risk Return Profile  
Volatility (Standard Deviation) 34.86% N/A N/A 39% F
Risk Adjusted Return 18.27% N/A N/A 44% F
Market Capitalization 0.35B 59% F 48% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 77.58 17% F 16% F
Price/Book Ratio 1.85 76% C 59% F
Price / Cash Flow Ratio 7.64 26% F 41% F
EV/EBITDA 24.34 38% F 32% F
Management Effectiveness  
Return on Equity -11.64% 70% C- 41% F
Return on Invested Capital 4.95% 83% B 60% D-
Return on Assets -3.16% 69% D+ 35% F
Debt to Equity Ratio 82.62% 35% F 29% F
Technical Ratios  
Short Ratio 8.15 37% F 17% F
Short Percent 7.45% 48% F 28% F
Beta 1.31 52% F 38% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.